AXONIS THERAPEUTICS, INC.
Oral small-molecule KCC2 enhancer drug (AXN-006-01-3) for restoring chloride homeostasis in spinal dorsal horn neurons
- Sector
- Biotech
- Headquarters
- Boston, MA
- Latest Form D
- $46M, Nov 2024
- Total capital
- $49.8M
- Federal grants
- $3.8M
- 7 awards · 2020–2024
- Rank in peer group#255 of 514
- Private capital raised
- $46M
- 1 Form D · last Nov 2024
- 24 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 21 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$46M
- Federal grantHealth and Human S · Phase I · Development of Oral KCC2 Potentiator AXN-027 as a Novel Anti-Epileptic Drug for Mesial Temporal Lobe Epilepsy$323K
- Federal grantHealth and Human S · Phase I · Development of oral KCC2 enhancer drug for treatment of painful diabetic neuropathy$300K
- Federal grantHealth and Human S · Phase II · Development of KCC2 Neuromodulators to Treat Paralysis After Spinal Cord Injury.$1.4M
- Federal grantHealth and Human S · Phase I · Development of Neuromodulating AAV-KCC2 Gene Therapy to Treat Paralysis, Spasticity and Neuropathic Pain after Spinal Cord Injury$336K
- Federal grantHealth and Human S · Phase I · Development of AAV-AXN-007 gene therapy to treat glaucoma.$299K
- Federal grantHealth and Human S · Phase II · Development of KCC2 neuromodulators to treat paralysis after spinal cord injury.$774K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Development of KCC2 neuromodulators to treat paralysis after spinal cord injury.$331K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
49months
from AXONIS THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Sep 2020
- Health and Human S · $331K
- First Form D · Nov 2024
- $46M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#255 · top 50%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Joanna StanickaResearcherExecutive Officer, DirectorLinked by $2.5M in grants as PI
- Shane . HegartyResearcherExecutive OfficerLinked by $934K in grants as PI
- Brock ReeveDirectorNamed in SEC Form D filings
- Corey . GoodmanDirectorNamed in SEC Form D filings
- Donald J. Manning, M.D., Ph.DExecutive OfficerNamed in SEC Form D filings
- Jeffrey ImbaroExecutive OfficerNamed in SEC Form D filings
Show all 8 people
- Jonathan J. LeffDirectorNamed in SEC Form D filings
- Raymond J. KelleherDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 21- PendingKCC2 Potentiators And Uses ThereofUSPTOApplication 19384068
- PendingKCC2 Potentiators And Uses ThereofUSPTOApplication 19343083
- PendingKCC2 Potentiators And Uses ThereofUSPTOApplication 19347965
Show all 21 patent records
- KCC2 Potentiators And Uses ThereofMar 5, 2026 · Application 19384068Pending
- KCC2 Potentiators And Uses ThereofJan 29, 2026 · Application 19343083Pending
- KCC2 Potentiators And Uses ThereofJan 29, 2026 · Application 19347965Pending
- Methods And Compounds For Inhibiting MKK7 EnzymesJan 15, 2026 · Application 18880127Pending
- KCC2 Potentiators And Uses ThereofApplication 63737455Pending
- KCC2 Potentiators And Uses ThereofApplication 63705307Pending
- KCC2 Potentiators And Uses ThereofApplication 63705308Pending
- KCC2 Potentiators And Uses ThereofApplication PCTUS2024028772Pending
- KCC2 Potentiators And Uses ThereofApplication 63575074Pending
- KCC2 Potentiators And Uses ThereofApplication PCTUS2024023319Pending
- KCC2 Potentiators And Uses ThereofApplication PCTUS2024023241Pending
- Methods And Compounds For Inhibiting MKK7 EnzymesApplication PCTUS2023026480Pending
- KCC2 Potentiators And Uses ThereofApplication 63465743Pending
- Methods And Compounds For Treating Neurological DisordersApplication PCTUS2023017917Pending
- KCC2 Potentiators And Uses ThereofApplication 63457326Pending
- Methods And Compounds For Inhibiting MKK7 EnzymesApplication 63357190Pending
- KCC2 Potentiators And Uses ThereofApplication PCTUS2025060669Pending
- Methods And Compounds For Treating Neurological DisordersApplication 63329207Pending
- KCC2 Potentiators And Uses ThereofApplication 63897197Pending
- KCC2 Potentiators And Uses ThereofApplication PCTUS2025050362Pending
- KCC2 Potentiators And Uses ThereofApplication PCTUS2025023285Pending
Related companies, and why
- VANGUARD THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- COLLABORATIONS PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Novan, Inc.Similar federal contract value in Biotech · null in contracts
- KIYATEC, LLCSimilar federal contract value in Biotech · null in contracts
- Mitokinin, Inc.Similar federal contract value in Biotech · null in contracts
- Suono Bio Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .